The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Kelley, Melissa Fishel receive $2.4M NCI grant to develop pancreatic cancer treatments

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Mark Kelley

Melissa Fishel

Mark Kelley and Melissa Fishel, two researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, received a five-year, $2.4 million grant from NCI to explore therapies that target the critical pathways pancreatic tumors use to survive.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 
Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
By Robert A. Winn, Otis W. Brawley and Preston Willett
PodcastThe Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
By Paul Goldberg and Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account